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Abstract
Background: This study aims to explore the feasibility of anchoring a four-arm transvaginal mesh (TVM) to the mid-
urethra to correct an anterior compartment POP–Quantification stage II–III (Q II–III) and concomitant genuine SUI.
Methods: We analysed clinical data from 248 patients with stage II–III anterior prolapse and concomitant SUI who
had undergone surgery at a tertiary referral centre in Hungary between January 2008 and June 2010. One hundred
and twenty-four women treated with anterior colporrhaphy and 62 patients implanted with a conventional
permanent TVM were selected as historical matched controls. Sixty-two patients received a modified permanent
TVM, where the mesh was fixed to the mid-urethra with two stitches for the purpose of potentially correcting SUI.
Surgical complications were classified using the Clavien–Dindo (CD) classification system.
Results: The anti-SUI efficacy was minimally higher in the mTVM group than in the original TVM group (p = 0.44,
96.8% vs 91.9%, respectively), while prosthesis surgery was more effective than anterior colporrhaphy in improving
the anterior compartment POP–Q status (96.8, 90.3% vs 64.5%, respectively). Anchoring the mesh did not increase
the extrusion rate (p = 0.11). The de novo urge symptoms were not more prevalent among those who had received
additional periurethral stitches (p = 1.00, 11.3% vs 12.9%). The incidence of reoperation observed in the mTVM
group was non-significantly lower than that in the TVM group (p = 0.15, 6.5% vs 16.1%); however, the difference did
not reach the level of significance. The early postoperative complication profile was more favourable among the
mTVM patients (classified as CD I: 8.1%; CD II: 1.6%; and CD IIIb: 1.6%) as compared to the TVM group (p = 0.013).
Conclusions: The new, modified mesh surgery represents an effective procedure for prolapse and concomitant SUI
with a decreased risk of short- and long-term complications.
Keywords: Modified transvaginal mesh, Transobturator tape, Anterior colporrhaphy, Complications, SUI with POP–Q II,
Clavien–Dindo classification
Background
Coexisting stress urinary incontinence (SUI) and pelvic
organ prolapse (POP) are highly prevalent (63–80%) [1], and
the cumulative risk of surgery for POP or SUI by the age of
80 years has been estimated at 11.1% [2, 3]. Despite the
availability of a wide variety of prolapse surgery, there is no
consensus on the optimal treatment. Vaginal prosthetic
surgery has been proposed for anterior compartment POP–
Quantification (Q) stage II–III (International Continence
Society/International Urogynecological Association) [4] in
view of the low recurrence rate (6.7–24%) [5–8] relative to
that after classical anterior colporrhaphy (30–40%) [6, 8, 9].
A recent Cochrane review confirms the superiority of
repairing prolapse of the mid-anterior vaginal wall with
permanent mesh over native tissue repair [8]. However, a
worldwide spread of a range of vaginal mesh operations has
resulted in a huge number of complications (e.g. infection,
extrusion and de novo urge symptoms). As a consequence,
the US Food and Drug Administration has published
warnings with the aim of restricting the utilization of vaginal
prosthesis to centres with specially trained surgeons after
patients have been thoroughly informed [10]. Furthermore,
it is assumed that a combination of a synthetic mesh with
the sling operation [11–13] will substantially increase the
cure rate of concomitant SUI. In contrast, the combined
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techniques represent an increased complication rate and
elevated financial burden.
It is well known that the supporting position of the
prosthesis differs slightly with the transvaginal mesh
(TVM) and transobturator tape (TVT-O). The TVT-O
sling is located under the mid-urethra, whereas the TVM
elevates the whole anterior and middle compartment [14].
TVM produces a significantly weaker anti-SUI effect com-
pared to that of the TVT-O since TVM elevates the
urinary bladder neck [7]. Furthermore, we hypothesise
that the original TVM operation can be followed by
residual SUI as the strengthening of the back arms may
result in a backward sliding of the entire mesh, leading to
a lack of suspension of the urethra.
We propose a modification of the four-arm TVM pro-
cedure in an attempt to achieve a better SUI correction,
without any decrease in prolapse repair efficacy. We
have developed a new method where the mesh is
sutured to the mid-urethra in order to prevent the back-
ward sliding, and, in this way, the anterior arms mainly
elevate the middle part of the urethra, potentially leading
to effective anti-incontinence. In other words, the an-
chored mesh takes over the function of the pubourethral
ligament, which should normally stabilize the urethra,
but is loose in SUI.
We demonstrate an alternative operative method for
POP–Q II–III repair and anti-incontinence with the
TVM fixed to the mid-urethra. The efficacy and short-
and long-term complication profiles of this new surgical
technique were compared with those of historical con-
trols involving original TVM and anterior colporrhaphy
operations at our departments.
Methods
The prospective longitudinal cohort study comprised 62
women who presented for the correction of SUI in con-
junction with symptomatic anterior compartment POP–Q
II–III at the Departments of Urology and Obstetrics and
Gynaecology, University of Szeged, Hungary, between
January 2010 and June 2010. The trial was conducted in
accordance with the IDEAL consensus. After the idea
(IDEAL stage 1) of concomitant surgery for SUI and POP
was developed, ten operations were performed with a high
cure rate of both symptoms in all cases after four weeks
(IDEAL stage 2). Based on these data, TVM or anterior
colporrhaphy and delayed TVT-O for SUI and coexisting
POP repair have been replaced by the new surgery in our
departments (IDEAL stage 3) [15]. The patients were
monitored during monthly outpatient appointments in
the first six months; thereafter, check-ups occurred every
half year. The Institutional Review Board regularly
reviewed the clinical data on the patients.
Our work was carried out in accordance with the Code
of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans and was
approved by the Ethics Committee, Faculty of Medicine,
University of Szeged (Protocol No. 194/2010). The
Institutional Review Board supervised patient monitoring.
Written informed consent was obtained from all partici-
pants after the advantages and possible complications of
the modified surgery were explained in detail.
All the patients who exhibited coexisting symptoms
(both SUI and POP–Q II–III) were recruited prospectively
into the study. The symptomatic POP–Q stage II–III an-
terior prolapse is defined as the maximum extent of the
prolapsed anterior vaginal wall being within 1 cm above
and 6 cm below the hymen [4, 16]. According to the inter-
national POP guidelines (the EBU and NICE guidelines)
[17, 18], if the condition disrupts the patient’s life and
nonsurgical treatment options have not helped, it should
be treated surgically. POP repair was considered effective
if a significant (> 1 cm) improvement was measured at
points Aa, Ba and C and in total vaginal length (TVL)
during the follow-up in accordance with the POP–Q
system (International Continence Society) [4, 16].
Anti-incontinence efficacy was determined if no further
SUI was diagnosed by urodynamic examination.
In all cases, urodynamic examinations comprising
uroflowmetry, cystometrography and abdominal leak
point pressure tests were performed before surgery to
objectively determine the coexisting symptomatic SUI
based on the international guidelines (the EBU and
NICE guidelines) [15, 16]. The abdominal leak point
pressure test was used as a standardised examination
method for the evaluation of SUI with urine leakage as a
sign. If the intraabdominal pressure recorded at the
point of urine leakage was less than 40 cmH2O, the
origin of the SUI was set as intrinsic sphincter deficiency
(ISD) [19]. In the case of ISD, preoperative pelvic floor
muscle training (PFMT) was recommended. If the
patient was unwilling to do PFMT or the training was
unsuccessful, a modified TVM operation was recom-
mended. This was also recommended in the case of sus-
pected urethral hypermobility – i.e. if the intraabdominal
pressure at the point of urine leakage was higher than 60
cmH2O. Preoperative irritating voiding symptoms were
not an exclusion criterion before the study.
All the data were collected prospectively. Further in-
clusion criteria in the study were negative urinary cultur-
ing and ineffective non-surgical treatment or patient’s
unwillingness to receive conservative treatment. The ex-
clusion criteria were as follows: occult SUI, a history of
mesh use or anti-incontinence pelvic procedures, anti-
depressant therapy, pregnancy, whether the patient was
in the puerperal period and up to six months
post-partum, and cancer of the pelvic organs.
There are no clear international recommendations on
surgical anterior compartment POP–Q II repair, but an
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increasing body of evidence suggests that TVM is a bet-
ter treatment option for anterior wall prolapse ≥ stage II
than traditional anterior colporrhaphy [7, 20, 21]. We
have modified the transobturator TVM operation re-
ported by Sergent et al. [7] by inserting two additional
stabilizing sutures which fix the anterior edge of the
mesh to the paraurethral tissues at the level of the
mid-urethra. All operations were carried out with 100%
polypropylene monofilament permanent meshes pro-
duced by Aspide® SURGIMESH® PROLAPSE (Aspide
Médical, La Talaudière, France). The implanted vaginal
prosthesis has pores which are 1.6 × 1.7 mm in size and
is approved for anterior vaginal repair.
Surgery was performed under general anaesthesia with
the patient in the lithotomy position with an indwelling
urinary catheter. The anterior vaginal wall was incised
longitudinally throughout its thickness from the cervix
to 1 cm below the urethral meatus, under the mid-ure-
thra. The thickness of the dissection, the location of the
vaginal incision, the placement of the mesh and the
closure of the incision varied only minimally, and the
length of the incision varied only between 6 and 7 cm.
Before insertion, all sterile meshes were soaked in iodic
fluid (Betadine®). The Surgimesh® device was introduced
beneath the dissection. Its four arms were then passed
through the obturator membrane. The posterior part of
the mesh was anchored to the anterior side of the
cervix using two Prolene® 2–0 sutures (Ethicon,
Issy-les-Moulineaux, France).
The mesh was then spread by securing its anterior
parts beneath the mid-urethra using two Vicryl 2–0®
absorbable sutures (Ethicon, Issy-les-Moulineaux,
France) and promoting the proper elevation and closure
of the urethra (Fig. 1). The mesh was then adjusted in a
tension-free manner beneath the distal part of the
urethra and bladder, and the anterior vaginal wall was
closed using Monocryl® 3–0 absorbable sutures (Ethicon,
Issy-les-Moulineaux, France) with a slight colpectomy.
All the operations were performed by the same two
experienced senior surgeons, and there were no dif-
ferences in the operative processes.
Prophylactic preoperative antibiotics (cefazolin 1 g,
amoxicillin and clavulanic acid 1.2 g or gentamycin
160 mg) were administered intravenously. A urinary
catheter was removed on the morning of the postoperative
day. A vaginal gauze pack (gauze soaked in Betadine
iodine) was placed for 12 h. The post-voided residual urine
was measured by ultrasonography before each patient was
discharged. All the patients participated in topical intravagi-
nal oestrogen cream treatment for at least twelve months
following the operation (Ovestin® 1 mg/gram daily), but
none of the patients took part in preoperative oral hormone
replacement therapy. The follow-up period after the modi-
fied TVM operation was 36 months.
The historical controls comprised 62 patients with
genuine SUI verified by urodynamic examination with
grades of POP II–III who had originally undergone a
TVM operation (control group I). A further 124 patients
with anterior compartment symptomatic POP–Q II and
any SUI corrected by anterior colporrhaphy operations
(control group II) were also operated on by the same
two senior surgeons at the departments. The data on the
historical controls were retrieved retrospectively from
the medical database between January 2008 and December
2009. Eligibility for the operation and consistent collection
of outcome measurements (operative characteristics and
post-operative findings) were tied to a follow-up schedule
which was routinely established in the historical groups.
This schedule was followed for the mTVM group as well.
The follow-up period in the control groups was also three
years. Baseline and follow-up evaluations after six weeks to
three years were performed by an experienced urogynaecol-
ogist. All the patients were given an appointment for the
subsequent medical consultation according to a follow-up
arrangement (Table 1). When a patient missed an appoint-
ment, a urogynaecologist reminded her by telephone, and,
hence, there was no registered loss due to lack of follow-up
in our samples. For each case, we matched controls in each
control arm (groups I and II) who were as similar as
possible in age, systemic diseases, and previous parity and
vaginal operations.
The factors studied were the demographic and patient
data, the intraoperative findings and postoperative
factors. Furthermore, the incidence of systemic chronic
diseases that might have a detrimental effect on the
healing process (i.e. in diabetes mellitus and auto-
immune diseases) was also recorded, and displacement
of the implant due to chronic coughing in airway
Fig. 1 Anchoring stitches stabilize the mesh position under
the mid-urethra
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diseases was also considered. As concerns the long-term
postoperative complications of the sling and mesh pro-
cedures, we determined the rejection rate, the presence
of de novo urge symptoms (DNUS) or urinary tract
infection (UTI), and the need for reoperation. The
diagnosis of DNUS was set if detrusor pressure changes
were detected in cystometrographic pressures after the
surgeries. The postoperative complications that led to
reoperation were infection, recurrent descent or incon-
tinence, implant extrusion, chronic pelvic pain and total
retention. Prosthetic extrusion was diagnosed by the
presence of exposed graft material in the vagina.
Post-void residual urine is a measurement of the urine
that remains in the bladder less than 20 min following
voiding which identifies urinary retention. Bladder
volumes that suggest urinary retention are commonly
defined as greater than 500 to 600 ml [22, 23]. DNUS
was classified as a sudden involuntary contraction of the
muscular wall of the bladder causing urinary urgency, an
immediate unstoppable urge to urinate with a postopera-
tive onset.
Operative and perioperative complications (six weeks
after the procedures) described after mTVM and
historical operations were collated, overall frequency
within all cases were calculated, and severity was graded
using the Clavien–Dindo classification comprising all
the follow-up periods. More specifically, additional
medication due to deviation from the normal postopera-
tive course (pain, fever, wound infection and minimal
bleeding) was categorized as Grade I, UTIs requiring
antibiotic treatment and SUI/POP without any postoper-
ative correction, DNUS or blood transfusion were
grouped as Grade II, and reoperation performed in
general anaesthesia was graded as IIIb [22].
Statistical analysis
The SPSS 17.0 program package was used to analyse the
data. The non-parametric design of the continuous
variables was verified with the Shapiro–Wilk test. The
categorical and continuous variables were compared
with the χ2 test and Kruskal–Wallis test, respectively.
Univariate logistic regression was employed to determine
the odds for continuous variables. Multiple logistic regres-
sion was used to adjust the comparisons of the groups in
terms of age, previous parity, postmenopausal stage, previ-
ous vaginal operations, chronic systemic diseases, POP–Q
stage and urge symptoms due to inequalities between
cases and controls. A two-tailed p-value of < 0.05 was
judged as significant. The power of the statistical tests
ranged between 74 and 99% in the study.
Results
Table 2 presents the baseline characteristics of the par-
ticipants in the study groups. Maternal age and BMI
were significantly higher among the mesh-operated
patients (p < 0.001 and p = 0.004, respectively). The vast
majority was postmenopausal in all groups; however, the
highest rate was noticed disproportionally among those
who had undergone mTVM (97%).
There was a trend of patients with modified mesh
having vaginal deliveries and vaginal operations at the
highest rate; however, the differences between the
groups were not significant. No significant differences
were observed between groups in any type of chronic
systemic diseases.
Table 3 lists the operative characteristics and compli-
cations, while Table 4 provides the odds and adjusted
odds of the differences in baseline and surgical charac-
teristics in the three study groups. The operation took a
similar amount of time in the mTVM group as com-
pared with the anterior colporrhaphy (Adjusted odds
rate (AOR): 1.03) or TVM (AOR: 0.97) control group.
The estimated blood loss during the operation was
significantly lower in the mTVM group than in control
group I (AOR: 0.96, p < 0.001) and control group II
(AOR: 0.96, p < 0.001). The occurrence of bladder injury
and the need for immediate postoperative blood transfu-
sion were negligible in all the study groups.
The reoperation rate was significantly the lowest in the
mTVM group at 6.5% as compared to that in the anterior
colporrhaphy group (32.1%) (AOR: 0.07, p < 0.001) and
that of 16.1% in the TVM group (AOR: 0.22, p = 0.15).
The rate of implant removal was lower among those
mesh-operated patients who had undergone the modified
Table 1 Schedule of assessments/data collection for both
Assessment Recruitment before
intervention phase
Intervention
(Surgery)
Follow-up
6 weeks 6 months 1 years 2 years 3 years
Written informed consenta x
Gynaecological examination: incontinence symptoms x x X x x x X
Gynaecological examination: prolapse x x X x x x X
Urodynamic examination x x X
Adverse events x X x x x X
Urine culture x x x x X
aavailable in the modified transvaginal mesh operated women
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technique than those with the original TVM (AOR: 0.13,
1.6% vs 9.7%, respectively); however, the difference did not
reach a significant level. One reoperation occurred in the
mTVM group due to apical compartment POP (1.6%), an-
other (1.6%) was performed due to anterior compartment
descent after the removal of the extruded mesh, a third
(1.6%) for SUI and a fourth (1.6%) for postoperative pain.
In addition, reoperation due to postoperative POP had a
frequency of 8.1%, and one patient (1.6%) required
reoperation due to SUI in the original TVM group. The
colporrhaphy patients needed more reoperations (32.1%),
and the difference was robust (AOR: 0.007). All the cases
involving POP recurrence (3.2 and 9.7%, AOR: 2.94) follow-
ing the two mesh operations were found in the untreated
compartment, posteriorly behind the mesh-supported area.
The recurrence of anterior compartment POP (35.5%,
p < 0.001) and SUI (38.7%, p < 0.001) or reoperation
due to recurrence of SUI (8.9%, AOR: 0.11, p = 0.06)
and POP (25.0%, AOR: 0.05, p < 0.001) during the
follow-up period was typical of the anterior colporrha-
phy patients. As expected, slightly more cases of SUI
were cured in the mTVM group than in the TVM
group (96.8% vs 91.9%), although the differences were
not significant (AOR: 2.98). Prolapse repair was
achieved in a significantly higher proportion of the
patients who underwent mTVM compared to their
anterior colporrhaphy counterparts (96.8% vs 64.5%,
AOR: 14.16 p < 0.001). Modification of the TVM
displayed a moderate effect on POP recurrence
compared to the original operation (9.7%) (AOR: 2.94,
p = 0.27). Urinary tract infection was not more preva-
lent after the prosthesis operations than after anterior
colporrhaphy. The rate of extrusion was nearly four
times higher in the TVM group than in the mTVM
group (AOR: 0.13, p = 0.11), with extrusion appearing
earlier in the group that underwent a non-modified
operation. All implants were removed because of the
extrusion of the vaginal wall. No rectal or bladder
fistula, pelvic abscess or haematoma was observed in
any of the groups.
Modifying the TVM technique led to a signicantly
higher elevation of point Aa compared to the traditional
TVM (AOR: 4.83) with a significantly reduced shorten-
ing of the vagina (AOR: 0.41). The mTVM significantly
improved the prolapse status (POP–Q of Aa, AOR:
142.9; Ba, AOR: 5.95; and C, AOR: 25.0) compared to
that of anterior colporrhaphy, whereas the total vaginal
length was significantly shortened (p < 0.001) (Table 5).
Table 6 demonstrates the postoperative complications
within six weeks according to the Clavien–Dindo classi-
fication. A total complication rate of 11.3% in the
mTVM group, 35.5% in the TVM group and 22.6% in
the colporrhaphy group was noted with significant differ-
ences (p = 0.013). Subanalyses were performed indicating
that the complications occurred with a non-significantly
lower prevalence among the mTVM participants
compared to the anterior colporrhaphy group (AOR: 0.56,
p = 0.3), whereas the difference was significantly lower in
the mTVM group than among the TVM participants
(AOR: 0.29, p = 0.02) (data are not shown). CD I compli-
cations predominantly occurred in the two groups of
women operated on with prostheses, whereas the
historical anterior colporrhaphy operations were followed
mostly by CD II.
Discussion
The most striking result of this study is that the transva-
ginal implantation of the four-arm mesh sutured to the
mid-urethra, a new modification of the TVM procedure
[7], is highly effective in the repair of an anterior
prolapse (POP–Q II–III) and in genuine stress urinary
incontinence (SUI). Success rates of 96.8 and 96.8% were
Table 2 Baseline characteristics of patients who presented for operation for POP–Q II–III and genuine SUI between January 2006
and December 2012
Modified TVM group
(N = 62)
Control group I
(historical controls: TVM) (N = 62)
Control group II (historical controls:
anterior colporrhaphy) (N = 124)
p value
Age (y) (mean ± S.D.) 62.9 ± 7.7 59.7 ± 10.1 55.9 ± 11.1 < 0.001
BMI (kg/m2) (mean ± S.D.) 29.4 ± 2.9 28.4 ± 3.0 27.8 ± 3.8 0.004
Previous vaginal deliveries (mean ± S.D.) 2.3 ± 1.2 2.1 ± 0.6 2.1 ± 0.8 0.71
Postmenopausal women, n (%) 60 (96.8) 47(75.8) 92 (74.2) 0.001
Previous vaginal operations, n (%) 24 (38.7) 14 (22.6) 36 (29.0) 0.14
Chronic systemic diseases, n (%) 17 (27.4) 16 (25.8) 18 (14.5) 0.06
Diabetes mellitus, n (%) 10 (16.1) 10 (16.1) 9 (7.3) 0.09
Autoimmune diseases, n (%) 4 (6.5) 3 (4.8) 5 (4.0) 0.77
Airway diseases, n (%) 5 (8.1) 3 (4.8) 6 (4.8) 0.64
All recruited patients presented for anterior compartment POP–Q II–III (pelvic organ prolapse) and genuine SUI (stress urinary incontinence). The modified
transvaginal mesh (mTVM) group comprised patients who received a four–arm mesh that was fixed to the mid-urethra. Control groups I and II include historical
controls who had participated in TVM and anterior colporrhaphy without any Kelly–Stoeckel suture, respectively
Chronic systemic diseases include diabetes mellitus, airway diseases and autoimmune diseases
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demonstrated for genuine SUI and prolapse, respectively.
This surgical procedure for prosthetic placement pro-
vided a minimally better SUI reconstructive effect than
that of the TVM procedure in our historical control
group (91.9%) or that reported in the literature (69–90.3%)
[24–26]. With regard to the POP repair, mTVM (96.8%)
proved significantly more effective than historical anterior
colporrhaphy (64.5%), but only minimally higher than that
of the non-modified, transobturator mesh technique in our
database (90.3%) and that demonstrated in the literature
(with a rate of 82.3–100%) [5, 20, 21, 26–29]. Fixing the
anterior arm of the mesh to the periurethral tissue elevates
point Aa significantly more effectively than the original
TVM with less vaginal shortening.
TVM supports the whole of the anterior and middle
compartments, but does not elevate the middle of the
urethra and, hence, theoretically allows for urethral
dorsal rotation, which may lead to residual SUI,
especially if the mesh is able to migrate a bit more pos-
teriorly toward the cervix. It is also possible that mesh
movements could be responsible for DNUS with the
traditional TVM method. Using stabilizing sutures to fix
the mesh to the paraurethral tissues at the level of the
mid-urethra, where the pubourethral ligament originally
held it, helps to elevate the middle region, this being con-
sidered the treatment of SUI that is at least as effective as
the TVT-O technique (91.2% in our non-published data
and 92% in the literature) [30]. In other words, anchoring
the anterior part of the mesh to the mid-urethra imitates
the mechanism of action of the mid-urethral sling as an
additional procedure for SUI correction. The original
TVM has a limited anti-SUI mechanism.
Furthermore, our results suggest a better anatomical
success rate after the mesh is fixed to the mid-urethra,
which may be explained by the lack of shrinkage and less
folding of the mesh. By contrast, our results might allow
for the speculation that prosthesis stabilization with
sutures to prevent any backward movement could lead
to prolapse recurrence in the untreated middle com-
partment, i.e. in the area not supported by the mesh.
We attribute our lower anatomical recurrence of
mTVM to a wider suspension area of the insertion of a
smooth, non-folded mesh. To check on this, we have
launched a further study at our department, in which
the posterior arms of the TVM are anchored towards
the pericervical ring to provide apical support.
Table 3 Operative characteristics and postoperative complications of patients who presented for operation for POP–Q II–III and
genuine SUI between January 2006 and December 2012
Modified TVM
group (N = 62)
Control group I (historical
controls: TVM) (N = 62)
Control group II (historical controls:
anterior colporrhaphy) (N = 124)
p value
POP grading
grade II 50 (80.6) 59 (95.2) 124 (100) < 0.001
grade III 12 (19.4) 3 (4.8) 0 (0)
Urge symptoms 8 (12.9) 2 (3.2) 7 (5.6) 0.08
Duration of operation (min) (mean ± S.D.) 37.8 ± 7.4 38.8 ± 6.0 34.9 ± 7.9 < 0.001
Estimated blood loss (ml) (mean ± S.D.) 48.7 ± 21.8 83.8 ± 41.2 74.0 ± 33.4 < 0.001
Intraoperative bladder injury, n (%) 1 (1.6) 0 (0) 0 (0) 0.22
Blood transfusion, n (%) 0 (0) 0 (0) 1 (0.8) 0.61
Reoperation, n (%) 4 (6.5) 10 (16.1) 40 (32.3) < 0.001
POP–Q, n (%) 2 (3.2) 5 (8.1) 31 (25.0) < 0.001
SUI, n (%) 1 (1.6) 1 (1.6) 11 (8.9) 0.04
Vaginal wall extrusion, n (%) 1 (1.6) 6 (9.7) 0 (0) 0.11
Postoperative bleeding, n (%) 0 (0) 3 (4.8) 1 (0.8) 0.06
Postoperative pain, n (%) 1 (1.6) 0 (0) 0 (0) 0.22
Total retention, n (%) 0 (0) 1 (1.6) 1 (0.8) 0.61
Successful treatment of POP–Q, n (%) 60 (96.8) 56 (90.3) 80 (64.5) < 0.001
Successful treatment of SUI, n (%) 60 (96.8) 47 (75.8) 76 (61.3) < 0.001
Urinary tract infection, n (%) 11 (17.7) 14 (22.6) 23 (18.5) 0.75
De novo urge incontinence, n (%) 7 (11.3) 8 (12.9) 0 (0) < 0.001
Average time to observed extrusion (months) (mean ± S.D.) 1 ± 0 13.7 ± 8.3 n.m.a 0.13
All recruited patients presented for anterior compartment POP–Q II–III (pelvic organ prolapse) and genuine SUI (stress urinary incontinence). The modified
transvaginal mesh (mTVM) group comprised patients who received a four–arm mesh that was fixed to the mid-urethra. Control groups I and II include historical
controls who participated in TVM and anterior colporrhaphy without any Kelly–Stoeckel suture, respectively. n.m.a, not measurable
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TVM corrects SUI subjectively in only 83.3% of cases
[7]. Furthermore, subvesical mesh towards the obturator
spaces in a total of 74 patients with a stage ≥2 anterior
prolapse was associated with a symptomatic SUI repair
in 72% of the cases, and cystocele was corrected in 97%
[27]. The current trend is to resolve the concomitant
SUI and POP in a single hospitalization session so as to
reduce medical costs and improve the patient’s satisfac-
tion, but the optimum use of anti-incontinence proce-
dures during pelvic reconstructive surgery remains a
matter of debate [31]. A combination of mesh with a
mid-urethral sling in one session has been scarcely studied
[12, 32]. When TVM was combined with a TVT-O oper-
ation [12, 32], the success rate for SUI was 87.8–93.2%
and that for anterior wall repositioning was 94.4–96%, i.e.
a similar anti-incontinence and anatomical reconstruction
rate than those in our study, though that follow-up was
for up to 60 months. More studies are needed to evaluate
whether the additional insertion of a TVT-O sling into a
mesh provides any additional improvement in the SUI
and POP cure rate as compared with a single TVM or
modified TVM.
Table 4 Crude odds ratios (OR) and adjusted OR (AOR) for confounders in various comparisons of patients who presented for
operation for POP–Q II–III and genuine SUI between January 2006 and December 2012
Modified TVM group vs Control group I
(historical controls: TVM)
Modified TVM group vs Control group II
(historical controls: anterior colporrhaphy)
p value Unadjusted OR
(95% CI)
Adjusted ORa
(95% CI)
p value Unadjusted OR
(95% CI)
Adjusted ORa
(95% CI)
Age 0.05 1.04 (1.00–1.08) 1.02 (0.97–1.08) < 0.001 1.07 (1.04–1.11) 1.05 (1.01–1.10)
BMI 0.05 1.13 (1.00–1.29) 1.12 (0.96–1.30) 0.001 1.14 (1.04–1.25) 1.13 (1.01–1.26)
Previous vaginal deliveries 0.26 1.28 (0.83–1.98) 1.57 (0.90–2.76) 0.45 1.15 (0.84–1.58) 1.18 (0.79–1.76)
Postmenopausal women 0.001 9.6 (2.09–4.35) 11.58 (1.78–75.1) < 0.001 10.44 (2.41–45.2) 8.09 (0.98–67.05)
Previous vaginal operations 0.08 2.16 (0.99–4.74) 2.16 (0.86–5.44) 0.19 1.54 (0.81–2.93) 1.29 (0.59–2.80)
Chronic systemic diseases 1.00 1.09 (0.49–1.41) 0.95 (0.37–2.41) 0.045 2.23 (1.05–4.71) 1.84 (0.77–4.41)
Diabetes mellitus 1.00 1.00 (0.38–2.60) 0.77 (0.16–4.46) 0.07 2.46 (0.94–6.11) 0.86 (0.19–3.88)
Autoimmune diseases 1.00 1.36 (0.29–6.33) 3.23 (0.41–25.67) 0.48 1.64 (0.43–0.34) 1.99 (0.34–11.59)
Airway disorders 0.72 1.72 (0.40–2.58) 0.90 (0.15–5.54) 0.51 1.73 (0.51–5.89) 0.4 (0.08–2.14)
POP–Q III vs II 0.02 4.71 (1.26–17.5) 6.32 (1.07–37.52) < 0.001 1.24 (1.10–4.40) 1.36 (1.08–4.10)
Urge symptoms 0.09 4.44 (0.90–21.74) 4.85 (0.91–25.94) 0.10 2.48 (0.85–7.18) 3.02 (0.84–10.90)
Duration of operation 0.41 0.98 (0.93–1.03) 0.97 (0.91–1.03) 0.22 1.05 (1.01–1.09) 1.03 (0.98–1.09)
Estimated average blood loss < 0.001 0.96 (0.95–0.98) 0.96 (0.94–0.98) < 0.001 0.96 (0.94–0.97) 0.96 (0.94–0.98)
Intraoperative bladder injuryb 1.00 1.02 (0.98–1.05) n.m.b 0.33 1.02 (0.99–1.05) n.m.b
Blood transfusion n.mb n.mb n.m.b 1.00 0.99 (0.98–1.01) n.m.b
Reoperationb 0.15 0.36 (0.11–1.21) 0.22 (0.04–1.10) < 0.001 0.15 (005–0.43) 0.07 (0.02–0.32)
POP 0.44 0.38 (0.07–2.04) 0.26 (0.04–1.96) < 0.001 0.10 (0.02–0.43) 0.05 (0.006–0.41)
SUI 1.00 1.00 (0.06–16.39) 0.19 (0.01–5.7) 0.06 0.17 (0.02–1.34) 0.11 (0.06–0.89)
Vaginal wall extrusion 0.11 0.15 (0.02–1.31) 0.13 (0.009–1.71) n.m n.m.b n.m.b
Bleeding 0.24 0.95 (0.90–1.01) n.m.b 1.00 0.99 (0.98–1.01) 0.89 (0.68–1.12)
Postoperative pain 1.00 1.02 (0.98–1.05) n.m.b 0.33 1.02 (0.99–1.05) n.m.b
Total retention 1.00 0.98 (0.95–1.02) n.m.b 1.00 0.99 (0.98–1.01) n.m.b
Successful treatment of POP–Q 0.27 3.22 (0.62–16.67) 2.94 (0.47–18.6) < 0001 16.5 (3.85–70.77) 14.16 (3.09–65.00)
Successful treatment of SUI 0.004 9.58 (2.09–43.9) 72.2 (8.56–606.65) < 0.001 18.95 (4.43–81.13) 96.2 (7.40–1250.0)
Urinary tract infection 0.66 0.74 (0.31–1.79) 0.70 (0.26–1.87) 1.00 1.95 (0.43–2.19) 0.92 (0.34–2.45)
De novo urge symptoms 1.00 0.86 (0.29–2.53) 0.89 (0.25–3.22) < 0.001 1.13 (1.03–1.23) 1.10 (1.06–1.19)
Average time to extrusion observed 0.99 n.m.b n.m.b n.m.b n.m.b n.m.b
All recruited patients presented for anterior compartment POP–Q II–III (pelvic organ prolapse) and genuine SUI (stress urinary incontinence). The modified
transvaginal mesh (mTVM) group comprised patients who received a four–arm mesh that was fixed to the mid-urethra. Control groups I and II include historical
controls who participated in TVM and anterior colporrhaphy without any Kelly–Stoeckel suture, respectively
OR, Odds ratio; 95% CI, 95% confidence interval,
Adjusted ORa, All variables were adjusted for age, previous parity, postmenopausal stage, previous vaginal operations and chronic systemic diseases, POP–Q stage
and urge symptoms. n.m.b, not measurable
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Surprisingly, the double-sling extrusion rate was ex-
tremely low (0–10%) [12, 32]. The corresponding figures
were 1.6% in our mTVM group and 9.7% among our
TVM participants, which is in agreement with the mean
value of 11.6% (ranging from 3.9 to 16%) reported in the
literature [4, 20, 24, 27, 33, 34]. The extrusion rate
generally correlates well with the prosthesis breadth;
however, we observed a remarkably higher extrusion rate
for mesh compared to that for modified mesh. One can
speculate that the lack of stabilizing sutures led to a
“folding/wrinkling” of the edge of the mesh, resulting in
a lifting up and compressing of the mucosa and
deranged periprosthetic vasculature. The reported inci-
dence of prosthesis exposure for double-sling operations
is not clear-cut. A wider and double prosthesis involves
a greater chance of bacterial colonization, and the
enhanced preparation may additionally impair blood
supply to the vaginal wall.
Anterior colporrhaphy is inferior to mesh procedures
with regard to the effectiveness of POP repair and
anti-incontinence both in our database and as reported by
others (37–85 and 54%, respectively) [20, 33, 35, 36]. The
mTVM greatly improved the POP–Q status in all exam-
ined compartments in the vagina compared to that of col-
porrhaphy. However, the perioperative complication rate
is diminished after non-mesh surgery (22.6%) compared
to that after implant surgery (35.5%). This is supported by
the literature data [20, 28, 35]; however, our modified
mesh procedure produced the lowest complication rate in
our dataset (11.3%). The robustly lower complication rate
after the mTVM can be partly explained by the fact that
the surgeons in the study received more training at the
time. It is of note that there are no studies which illustrate
the perioperative, short-term complications of these geni-
tourinary surgeries.
In a single TVM series with the Perigee technique, the
average blood loss was found to be 180 ml [33], which
was much higher than in our mTVM data series
(48.7 ml), and the mean procedure duration was also
shorter in the mTVM group (37.8 min vs. 60.9 min)
[36].
One of the most frequent long-term complications we
observed with synthetic mesh materials in our series was
DNUS (11.3% and 12.9), which is an important indicator
of the level of patient satisfaction. Post-operative urody-
namic examinations showed detrusor muscle action in
all the cases suffering from DNUS. The average detrusor
muscle pressure was 7.75 cmH2O postoperatively,
whereas no sign of detrusor or intravesical pressure ele-
vation was detected preoperatively. We believe that one
possible reason for this is the fact that the mesh cannot
slide backwards and cannot press the urethra to the
bladder neck after the TVM is modified. The average
reported prevalence of de novo dyspareunia following
vaginal placement of a polypropylene mesh is 14% [37],
i.e. significantly higher than in our study (1.6%) (the data
are not presented in a table). Mesh+sling operations
impair the pelvic blood circulation and induce de novo
urge symptoms and pelvic pain; however, the reported
extrusion rate was 10% [32].
Our study had some limitations. The baseline charac-
teristics of the patients were not equally distributed in
the groups, and, hence, statistical adjustments were used
in multivariate analyses. A further limitation of the study
is its non-randomized manner. The surgeons became
better trained in the operative techniques, a fact which
may somehow bias the results. Moreover, it was not an
aim of the study to determine the subjective curative
rate of SUI or POP; however, the prospectively collected
objective curative frequency was noted. Furthermore,
different types of complications occur after anterior
colporrhaphy compared to mesh operations (i.e. extru-
sion does not occur after colporrhaphy), and the total
complication rate should be interpreted with caution.
Table 6 Clavien–Dindo classification for postoperative surgical complications among patients who presented for operation for
POP–Q II–III and genuine SUI between January 2006 and December 2012
Clavien–Dindo
gradea
Complications Modified TVM group
(N = 62)
Control group I
(historical controls: TVM)
(N = 62)
Control group II
(historical controls: anterior colporrhaphy)
(N = 124)
p value
I Non–pharmacologically
treated postoperative
bleeding, fever,
wound infection
5 (8.1) 12 (19.4) 11 (8.9) 0.013
II Urinary tract infection,
post–void residual volume,
blood transfusion,
treatment for de novo
urge symptoms
1 (1.6) 7 (11.3) 16 (12.9)
IIIb Reoperation for
vaginal wall extrusion
1 (1.6) 3 (4.8) 1 (0.8)
Total complications 7 (11.3) 22 (35.5%) 28 (22.6) 0.015
CD, Clavien–Dindo. aNo grade IIIa, IVa, IVb or V complication occurred. bData are expressed as n (%)
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Conclusions
In summary, use of a modified transvaginal mesh re-
sulted in a higher rate of treatment success than the
traditional mesh operation or non-mesh reconstructive
surgery (colporrhaphy) for repair of anterior vaginal-wall
prolapse and stress incontinence. By seeking a balance
between the highly effective anti-incontinence and POP
repair of the prosthesis operations and the less harmful
non-mesh repairs, the mTVM could be a reasonable
choice with a high SUI and coexisting POP reconstruct-
ive effect, thus ensuring lower rates of intra- and postop-
erative adverse events. Further randomized studies are
therefore necessary to compare the efficacy of this novel
intervention with that of double-sling procedures.
Abbreviations:
CD: Clavien–Dindo classification system; DNUS: De novo urge symptoms;
ISD: Intrinsic sphincter deficiency; mTVM: Modified transvaginal mesh
operation; PFMT: Pelvic floor muscle training; POP: Pelvic organ prolapse;
POP–Q II: Pelvic organ prolapse quantification system stage II; SUI: Stress
urinary incontinence; TVL: Lotal vaginal length; TVM: Transvaginal mesh
operation; TVT-O: Transobturator tape operation; UTI: Urinary tract infection
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